Protagonist Therapeutics, Inc (PTGX) income statement
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30206% above fair value
$127.16+2.49 (+2.00%)
Close on Nov 18, 2026Market cap $8.23BP/E 123.5Yield –
Protagonist Therapeutics, Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 20.7%
- Net margin
- 29.4%
- Return on equity, FY2025
- -20.2%
Financial strength
- Current ratio
- 21.71
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1129.8%
Valuation
- P/E ratio
- 123.5
- Price to sales
- 29.18
- Price to book
- 9.78
- Dividend yield
- –
See a number that looks wrong?